Contributed by Freenome
Too many people miss recommended cancer screening. Personalized Cancer Detection is Freenome’s approach to blood-based screening. It combines screening informed by each patient’s risks and needs with Freenome’s SimpleScreen™ portfolio of indication-specific tests.
SimpleScreen Lung provides a blood-based lung cancer screening option for eligible patients. When colorectal screening is also appropriate, SimpleScreen CRC is available as an add-on to the SimpleScreen Lung order, allowing both tests to be completed through one blood draw.
These options add to established screening methods, giving care teams another way to support screening participation.
Explore resources for providers
About Freenome
Freenome is a biotechnology company developing blood-based screening tests designed to detect cancer earlier, when it may be easier to treat. Its Personalized Cancer Detection (PCD) approach to blood-based screening is delivered through the SimpleScreen™ portfolio of indication-specific tests. Behind the portfolio is the Freenome Discovery Platform, which uses multiomics and AI/ML to identify the biological signals most informative for each indication. These insights help optimize each SimpleScreen test and guide portfolio expansion to address a broader range of cancer risks over time. Freenome partners with health systems to support a more personalized and connected approach to screening.
To learn more, visit www.freenome.com




